SpinalCyte Announces Issuance of New Chondrocyte Patents in the U.S. and Japan

3/11/19: The company’s patent portfolio now includes 39 U.S. and international patents issued with 100+ patents pending focused on the clinical use of fibroblasts. The company received IND clearance from the FDA in November to continue clinical trials into its lead fibroblast cell therapy product, CybroCell, in the treatment of degenerative disc disease.